An AllTrials project

NCT01734850: A reported trial by Calimmune, Inc.

This trial has reported on time, in line with the regulations.

Full data

Full entry on ClinicalTrials.gov NCT01734850
Title An Adaptive Phase I/II Study of the Safety of CD4+ T Lymphocytes and CD34+ Hematopoietic Stem/Progenitor Cells Transduced With LVsh5/C46, a Dual Anti-HIV Gene Transfer Construct, With and Without Conditioning With Busulfan in HIV-1 Infected Adults Previously Exposed to ART
Results Status Reported
ACT or pACT? This is what FDAAA officially calls a "probable Applicable Clinical Trial"
Start date April 30, 2013
Completion date Sept. 30, 2017
Required reporting date Sept. 30, 2020, midnight
Actual reporting date June 25, 2020
Date last checked at ClinicalTrials.gov Feb. 9, 2024
Days late None